Future studies exploring vitamin C metabolism in AML blasts are warranted to unravel its metabolic effects and role in blasts proliferation in a variety of scenarios (e.g., TET2-IDH1/2 mutants) to identify the categories of patients who may benefit the most from its therapeutic supplementation. The gene discussed is IDH1; the disease is acute myeloid leukemia.